SG Americas Securities’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4M | Buy |
161,552
+128,776
| +393% | +$3.07M | ﹤0.01% | 1118 |
|
|
2025
Q4 | $765K | Sell |
32,776
-50,914
| -61% | -$1.13M | ﹤0.01% | 2225 |
|
|
2025
Q3 | $1.65M | Buy |
83,690
+75,776
| +957% | +$1.56M | 0.01% | 1059 |
|
|
2025
Q2 | $172K | Buy |
7,914
+1,184
| +18% | +$27.9K | ﹤0.01% | 2359 |
|
|
2025
Q1 | $163K | Sell |
6,730
-26,082
| -79% | -$587K | ﹤0.01% | 2680 |
|
|
2024
Q4 | $685K | Buy |
32,812
+24,102
| +277% | +$518K | ﹤0.01% | 1090 |
|
|
2024
Q3 | $173K | Buy |
+8,710
| New | +$161K | ﹤0.01% | 2612 |
|
|
2023
Q4 | – | Sell |
-42,944
| Closed | -$502K | – | 3159 |
|
|
2023
Q3 | $502K | Buy |
+42,944
| New | +$574K | 0.01% | 1766 |
|
|
2023
Q2 | – | Sell |
-30,014
| Closed | -$498K | – | 2449 |
|
|
2023
Q1 | $498K | Buy |
30,014
+14,002
| +87% | +$231K | 0.01% | 1724 |
|
|
2022
Q4 | $298K | Sell |
16,012
-8,592
| -35% | -$132K | ﹤0.01% | 1928 |
|
|
2022
Q3 | $316K | Sell |
24,604
-65,852
| -73% | -$780K | ﹤0.01% | 1941 |
|
|
2022
Q2 | $634K | Sell |
90,456
-11,779
| -12% | -$86.4K | 0.01% | 1741 |
|
|
2022
Q1 | $848K | Sell |
102,235
-109,207
| -52% | -$772K | 0.01% | 1543 |
|
|
2021
Q4 | $1.43M | Buy |
211,442
+121,169
| +134% | +$797K | 0.01% | 1360 |
|
|
2021
Q3 | $478K | Buy |
+90,273
| New | +$494K | ﹤0.01% | 2552 |
|
|
2021
Q1 | – | Sell |
-10,203
| Closed | -$34K | – | 3323 |
|
|
2020
Q4 | $34K | Sell |
10,203
-100,939
| -91% | -$339K | ﹤0.01% | 3175 |
|
|
2020
Q3 | $330K | Buy |
+111,142
| New | +$435K | ﹤0.01% | 1883 |
|
|
2020
Q2 | – | Sell |
-20,148
| Closed | -$78K | – | 3710 |
|
|
2020
Q1 | $78K | Sell |
20,148
-20,088
| -50% | -$82.5K | ﹤0.01% | 3077 |
|
|
2019
Q4 | $151K | Buy |
+40,236
| New | +$188K | ﹤0.01% | 2685 |
|
|
2018
Q3 | – | Sell |
-12,576
| Closed | -$39K | – | 3187 |
|
|
2018
Q2 | $39K | Sell |
12,576
-4,809
| -28% | -$14.6K | ﹤0.01% | 3202 |
|
|
2018
Q1 | $42K | Buy |
+17,385
| New | +$57.8K | ﹤0.01% | 3102 |
|
|
2017
Q4 | – | Sell |
-57,050
| Closed | -$144K | – | 3252 |
|
|
2017
Q3 | $144K | Buy |
+57,050
| New | +$156K | ﹤0.01% | 2878 |
|
|
2016
Q2 | – | Sell |
-54,123
| Closed | -$63K | – | 2662 |
|
|
2016
Q1 | $63K | Buy |
+54,123
| New | +$84K | ﹤0.01% | 2732 |
|
|
2015
Q4 | – | Sell |
-28,400
| Closed | -$85K | – | 2735 |
|
|
2015
Q3 | $85K | Buy |
+28,400
| New | +$123K | ﹤0.01% | 1906 |
|
Other funds holding CPRX
VCM
DM
VPM
SG Americas Securities's CPRX Position: Q1 2026 in Review
SG Americas Securities increased its Catalyst Pharmaceutical (CPRX) stake by 393% in Q1 2026, buying an estimated $3.07M and bringing the position to 161,552 shares worth $4M. The position accounts for ﹤0.01% of the portfolio, ranked #1118.
SG Americas Securities first reported a position in CPRX in Q3 2015 and has held it in 24 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- SG Americas Securities held 161,552 shares of Catalyst Pharmaceutical worth $4M as of Q1 2026.
- SG Americas Securities bought 128,776 Catalyst Pharmaceutical shares in Q1 2026, an estimated $3.07M.
- Catalyst Pharmaceutical made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1118 holding.
- SG Americas Securities first reported a position in Catalyst Pharmaceutical in Q3 2015 and has held it in 24 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.